Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Molecular Templates Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MTEM
Nasdaq
8731
https://mtem.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Molecular Templates Inc
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
- Apr 9th, 2024 12:11 pm
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
- Mar 29th, 2024 12:21 pm
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
- Mar 28th, 2024 12:11 pm
Molecular Templates, Inc. Provides Interim Update
- Mar 4th, 2024 1:11 pm
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 8th, 2024 10:55 pm
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
- Nov 13th, 2023 9:11 pm
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
- Nov 2nd, 2023 8:11 pm
Molecular Templates to Participate in Upcoming Investor Conferences
- Nov 1st, 2023 8:12 pm
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
- Sep 28th, 2023 8:11 pm
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)
- Aug 25th, 2023 12:50 pm
Molecular Templates Announces 1-for-15 Reverse Stock Split
- Aug 11th, 2023 3:22 pm
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
- Aug 10th, 2023 12:08 pm
Molecular Templates Announces Executive Leadership Changes
- Aug 2nd, 2023 8:11 pm
Molecular Templates Announces Up to $40 Million Private Placement Offering
- Jul 13th, 2023 12:14 pm
Molecular Templates Announces Debt Payoff and Restructuring
- Jun 17th, 2023 12:56 am
Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma
- Jun 1st, 2023 11:57 am
Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 26th, 2023 9:10 pm
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
- May 15th, 2023 8:13 pm
Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know
- May 4th, 2023 2:00 pm
Scroll